Key result
Protocol evaluates TTR-stabilisers versus usual care for mortality and HF hospitalisations in ATTR-CM.
Why the study?
The effects of TTR-stabilising medicines (tafamidis and acoramidis) compared to usual care or placebo on all-cause mortality and heart failure hospitalisations in people with ATTR-CM needed systematic assessment.
Do TTR-stabilising medicines (tafamidis and acoramidis) reduce all-cause mortality and heart failure hospitalisations compared to usual care or placebo in people with ATTR-CM?
Systematic Review
Do TTR-stabilising medicines (tafamidis and acoramidis) reduce all-cause mortality and heart failure hospitalisations compared to usual care or placebo in people with ATTR-CM?
Answers are grounded in this paper and cite their sources.
This Cochrane review protocol outlines the methodology to systematically evaluate the effects of TTR-stabilising medicines (tafamidis and acoramidis) on mortality and heart failure hospitalisations in patients with transthyretin amyloid cardiomyopathy.
OBJECTIVES: This is a protocol for a Cochrane review (intervention). The objectives are as follows: Primary objective To assess the effects of TTR-stabilising medicines (tafamidis and acoramidis) compared to usual care or placebo on all-cause mortality and heart failure hospitalisations in people with ATTR-CM. Secondary objectives To assess the effects of tafamidis and acoramidis compared to usual care or placebo in people with ATTR-CM according to the following predefined subgroups. Demographic subgroups, including ethnicity and sex ATTR subtype (ATTRwt versus ATTRv) Disease severity, according to NYHA functional class.
No takes yet. Share an insight, caveat, or question.
Garbutt et al. (2026) conducted a systematic review in Transthyretin amyloid cardiomyopathy (ATTR-CM). TTR-stabilising medicines (tafamidis and acoramidis) vs. Usual care or placebo was evaluated on All-cause mortality and heart failure hospitalisations. TTR-stabilising medicines (tafamidis and acoramidis) will be assessed versus usual care or placebo for all-cause mortality and heart failure hospitalisations in ATTR-CM in this review protocol.
Synapse has enriched 10 related papers. Consider them for comparative context: